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Myosin Binding Protein-C slow (sMyBP-C) comprises a complex family of proteins
expressed in slow and fast type skeletal muscles. Similar to its fast and cardiac
counterparts, sMyBP-C functions to modulate the formation of actomyosin cross-bridges,
and to organize and stabilize sarcomeric A- and M-bands. The slow form of MyBP-C was
originally classified as a single protein, however several variants encoded by the single
MYBPC1 gene have been recently identified. Alternative splicing of the 5′ and 3′ ends of
the MYBPC1 transcript has led to the differential expression of small unique segments
interspersed between common domains. In addition, the NH2-terminus of sMyBP-C
undergoes complex phosphorylation. Thus, alternative splicing and phosphorylation
appear to regulate the functional activities of sMyBP-C. sMyBP-C proteins are not
restricted to slow twitch muscles, but they are abundantly expressed in fast twitch
muscles, too. Using bioinformatic tools, we herein perform a systematic comparison of
the known human and mouse sMyBP-C variants. In addition, using single fiber westerns
and antibodies to a common region of all known sMyBP-C variants, we present a detailed
and comprehensive characterization of the expression profile of sMyBP-C proteins in the
slow twitch soleus and the fast twitch flexor digitorum brevis (FDB) mouse muscles. Our
studies demonstrate for the first time that distinct sMyBP-C variants are co-expressed in
the same fiber, and that their expression profile differs among fibers. Given the differential
expression of sMyBP-C variants in single fibers, it becomes apparent that each variant or
combination thereof may play unique roles in the regulation of actomyosin cross-bridges
formation and the stabilization of thick filaments.
Keywords: MYBPC1, skeletal muscle, single fiber expression
INTRODUCTION
Myosin Binding Protein-C (MyBP-C) is a family of accessory
proteins that contributes to the assembly and stabilization of
thick filaments, and the formation of actomyosin cross-bridges
via direct interactions with both filamentous systems (Martyn,
2004; McClellan et al., 2004; De Tombe, 2006; Oakley et al.,
2007; James and Robbins, 2011; Ackermann et al., 2013). The
slow isoform of MyBP-C, encoded by the single MYBPC1
gene (Figure 1A), is composed of 7 immunoglobulin (Ig) and
3 fibronectin-III (Fn-III) domains, numbered from the NH2-
terminus as C1–C10 (Figures 1B,C, shown as white and gray
ovals, respectively). The C1 domain is preceded by a sequence
of ∼50 amino acids that contains a high percentage of pro-
line and alanine residues, referred to as Pro/Ala rich motif
(Figures 1B,C, shown as a dark gray horizontal rectangle), and
is followed by a conserved linker region of ∼100 amino acids,
termed M-motif (Figures 1B,C, shown as a light gray horizontal
rectangle).
Striated muscles contain three forms of MyBP-C: cardiac, slow
skeletal, and fast skeletal, cMyBP-C, sMyBP-C, and fMyBP-C,
respectively (Yamamoto and Moos, 1983; Weber et al., 1993;
Yasuda et al., 1995; Carrier et al., 1997; Shaffer and Harris,
2009). Single transcripts have been identified for the mammalian
cardiac and fast skeletal isoforms, encoding proteins of ∼140
and ∼130 kDa, respectively (Einheber and Fischman, 1990;
Weber et al., 1993; Yasuda et al., 1995). However, sMyBP-
C is unique, as there are several mammalian variants that
have been reported (Figures 1B,C) ranging in size from ∼115
to 130 kDa (Ackermann and Kontrogianni-Konstantopoulos,
2010). These differ by small segments of amino acids within
the Pro/Ala rich motif, the M-motif, domain C7, and the
extreme COOH-terminus. The different sMyBP-C variants are
co-expressed in variable amounts and combinations in both
slow and fast twitch skeletal muscles where they co-exist with
fMyBP-C (Ackermann and Kontrogianni-Konstantopoulos, 2010,
2011).
MyBP-C localizes along the length of the thick filaments
mainly occupying the C-zones of A-bands (Offer et al., 1973;
Bennett et al., 1986; Carrier et al., 1997). Similar to its fast and car-
diac counterparts, the majority of sMyBP-C variants are targeted
to the C-zone. Recent findings, however, have demonstrated that
select sMyBPC variants that possess a unique COOH-terminus
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FIGURE 1 | Human and mouse sMyBP-C variants. Domain architecture of
human and mouse sMyBP-C variants as listed in NCBI, Ensembl, and Vega
illustrating their common domains and unique segments. (A) Exons 1-33 of
the human MYBPC1 gene; the 5′ and 3′UTRs are denoted in black. Dark gray
boxes correspond to exons encoding the Pro/Ala rich region and the M-motif,
while the white and light gray boxes represent exons that encode Ig and FNIII
domains, respectively. Exons highlighted by a color are alternatively spliced
and encode unique regions of the sMyBP-C variants. Alternative splicing of
the sMyBP-C transcript in both humans (B) and mice (C) results in the
generation of several variants that share common domains, but also contain
unique short sequences in the NH2-terminus, the M-motif, the C7 domain,
and the COOH-terminus.
preferentially localize to the periphery of the M-band where they
interact with the giant cytoskeletal protein obscurin and function
to stabilize the M-band (Ackermann et al., 2009). Recent studies
focusing on sMyBP-C indicated that its NH2-terminus (including
the Pro/Ala rich motif, domain C1, and the M-motif) inter-
acts directly with actin and heavy meromyosin (HMM), and
modulates actomyosin binding and sliding in a variant-specific
manner (Ackermann et al., 2013). Interestingly, the Pro/Ala rich
motif and the M-motif present in the NH2-terminus of sMyBP-
C undergo extensive phosphorylation mediated by PKA and
PKC (Ackermann and Kontrogianni-Konstantopoulos, 2011);
however, the physiological significance of this modification is
currently unknown.
Herein we present a comprehensive overview of the known
human and mouse sMyBP-C variants, and provide evidence that
the expression profile of mouse sMyBP-C differs among fibers of
the same skeletal muscle. We also demonstrate for the first time
that multiple variants of sMyBP-C are co-expressed within a sin-
gle fiber, and that their expression correlates with the presence of
select myosin isoforms. Lastly, we discuss recent findings indicat-
ing the complex regulation of sMyBP-C mediated by alternative
splicing and phosphorylation.
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MATERIALS AND METHODS
DATABASE SEARCH
Human and mouse sMyBP-C variants were identified from
three prominent databases: NCBI (http://www.ncbi.nlm.nih.
gov/), Ensembl (http://www.ensembl.org), and Vega (http://vega.
sanger.ac.uk/index.html). To classify the product of a transcript
as a complete variant, the transcript should contain at least par-
tial 5′ and/or 3′ UTRs and include defined start and stop codons.
Little is known about alternatively splicing within themouse tran-
script, therefore any partial mouse sMyBP-C variants that were
listed in the above databases were included in the compilation,
shown in Figure 1. Most variants, with the exception of human
variants 002 and 013 were identified in all three databases, there-
fore their NCBI accession numbers are noted in Table 1. Human
variants 002 and 013 were identified in both Ensembl and Vega
databases; the accession number for the Ensembl database is
included in Table 1.
TISSUE COLLECTION AND SINGLE FIBER ISOLATION
Female C57BL6 mice were euthanized in accordance with pro-
tocols approved by the Institutional Animal Care and Use
Committee of the University of Maryland School of Medicine
and the NIH guidelines, and flexor digitorum brevis (FDB) and
soleus muscles were dissected. Primary cultures of FDB and
soleus muscle fibers were prepared as previously described (Liu
et al., 1997; Calderon et al., 2009), with minor modifications
in the preparation of single soleus fibers. In brief, soleus mus-
cles were incubated in DMEM (Gibco, Carlsbad, CA) in the
presence of 2µg/ml type 1 collagenase (Sigma, St. Louis, MO)
at 37◦/5% CO2for 3 h, followed by incubation in DMEM sup-
plemented with 0.75µg/ml type 1 collagenase at 37◦/5% CO2
overnight. Treated soleus muscles were gingerly teased apart
with fine, fire-polished tweezers and incubated at 37◦/5% CO2
for an additional hour. Following enzymatic digestion, fresh
media was added to the fiber preparations, and single FDB and
soleus fibers were picked under an inverted light microscope fit-
ted with a 4x objective. Individual fibers were placed directly
into 1x NuPAGE sample buffer (Life Technologies, Carlsbad,
CA) containing 10mM NaPO4, pH 7.2, 2mM EDTA, 10mM
NaN3, 120mM NaCl, and 1% NP-40, and analyzed by western
blotting.
WESTERN BLOTTING
Whole muscle FDB and soleus lysates were prepared as previ-
ously described, (Ackermann et al., 2009). Briefly, tissues were
homogenized in 10mM NaPO4, pH 7.2, 2mM EDTA, 10mM
NaN3, 120mM NaCl, and 1% NP-40 in the presence of pro-
tease inhibitors (Roche Applied Science), incubated on ice for
2 h with occasional mixing, and centrifuged at 14,000 × g for
30min at 4◦C. Approximately 30µg of protein lysates from each
tissue was heated at 90◦ for 5min. Similarly, single soleus and
FDB fibers were homogenized in the buffer described above,
and heated at 90◦ for 10min. Both whole muscle and single
fiber samples were separated by 4–12% SDS-PAGE using MOPS
buffer (Life Technologies). The top part (above ∼175 kDa) of
each gel was stained with Sypro Ruby total protein stain (Life
Technologies) for evaluation of myosin isoforms. The bottom
part of each gel (below ∼175 kDa) was transferred to nitrocel-
lulose (15V, 16 h, 4◦C) and probed with an antibody recogniz-
ing epitopes in Ig domain C5, which is common to all known
sMyBP-C variants (MYBPC1, Sigma; 1:1000). Each nitrocellu-
lose membrane was stained with Ponceau red dye to evalu-
ate loading. Loading among FDB or soleus fibers was similar
with only slight discrepancies, likely due fiber size differences.
A total of 48 soleus and 41 FDB fibers were analyzed. The
molecular weight of each immune-reactive band was calculated
Table 1 | Human and mouse variants of sMyBP-C.
Variant NH2-terminus M-motif Domain C7 COOH-terminus MW (kDa) Protein accession #
Exon 2 Exon 3 Exon 4 Exon 5 Exon 10 Exon 23 Exon 31 Exon 32 Exon 33
h−v1 + + + + + − + + 3′UTR 131.5 NP_002456
h−v2 + + + + + − − + 3′UTR 129 NP_996555
h−v3 + + − − + + − + 3′UTR 128 NP_996556
h−v4 + + − − + − − + 3′UTR 126.5 NP_996557
h−v5 + + − − + + + − + 131.5 NP_001241647
h−v6 + + − − + − + + 3′UTR 129 NP_001241648
h−v7 − + − − + − + + 3′UTR 128 NP_001241649
h−v8 + + − − − − + + 3′UTR 127 NP_001241650
h−v9 − − − − + − + + 3′UTR 126 NP_001241651
h−v10 − − + − + − − − + 128 NP_001241652
h−v002 + − − − + − + + 3′UTR 127.5 ENSP00000447362*
h−v012 − − − − + − − + 3′UTR 115.5 EAW97667.1
h−v013 + + + − + + − + 3′UTR 129.5 ENSP00000447660*
h−v202 + + − − + + + + 3′UTR 131 EAW97664.1
m−v4 + + − − + − − + 3′UTR 126 NP_780627
m−v002 + − − − + − + + 3′UTR 126.5 NP_00123930 1
*Proteins identified in the Ensembl Database.
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using standard methods as previously described (Anderson et al.,
1974).
RESULTS AND DISCUSSION
ALTERNATIVE SPLICING OF THE MYBPC1 TRANSCRIPT RESULTS IN A
COMPLEX FAMILY OF PROTEINS
MyBP-C slow was originally identified as a single protein, sim-
ilarly to its close relatives, the fast and cardiac isoforms (Weber
et al., 1993; Yasuda et al., 1995). Extensive technological advance-
ments of the last decade, however, shed light on the complexity of
many transcriptomes revealing the presence of several, previously
unidentified, transcript variants originating from single genes. An
outstanding example of these efforts is MYBPC1, the gene that
encodes sMyBP-C. MyBP-C slow is a heterogeneous family of
proteins resulting from extensive exon shuffling (Table 1), which
primarily takes place in its NH2 and COOH termini. Given the
great complexity of the sMyBP-C family, we performed a com-
prehensive analysis of all known sMyBP-C transcripts deposited
in the NCBI and Ensembl databases, focusing on the human
(h) and mouse (m) variants (v), as they are the most highly
studied. For consistency purposes, we use the term “variant”
to refer to the different sMyBP-C proteins, while we use the
term “isoform” to refer to the cardiac, slow, and fast MyBP-C
proteins.
To date, 14 sMyBP-C transcripts have been identified in the
human transcriptome, encoding 14 unique variants differing
only by short segments of amino acids (Figure 1 and Table 1).
Of the 33 exons that make up the human sMyBP-C transcript
(Figure 1A), nine of them are shuffled in and out during fif-
teen splicing events (Figure 1B). In contrast, only two full length
and two partial variants have been identified in the mouse tran-
scriptome (Figure 1C). Accordingly, seven splicing events have
been identified in the mouse sMyBP-C transcript, resulting in
the differential expression of six exons. In humans and mice,
the regions that encode the extreme NH2 and COOH termini
appear to be “hot-spots” for exon shuffling, although domain
C7 also undergoes splicing in both species, and the M-motif in
humans.
Splicing within the Pro/Ala rich region at the extreme NH2-
terminus of human sMyBP-C results in the shuffling of exons 2–5,
yielding 7 possible combinations (Figure 2A). Exons 2–5 are
arranged in frame and possess 33, 39, 36, and 33 nucleotides,
thus encoding 11, 13, 12, and 11 amino acid residues, respec-
tively. sMyBP-C h-v1 and h-v2 contain all four exons, whereas
h-v3, h-v4, h-v5, h-v6, h-v8, and h-v202 include exons 2 and 3
but lack exons 4 and 5. Human v013 lacks only exon 5, while
h-v002, h-v7, and h-v10 retain only one of the four exons, specif-
ically exon 2, 3, and 4, respectively. Lastly, h-v9 is missing all four
exons, while the start codon for h-v012 is in the middle of exon
7, resulting in a protein that lacks the Pro/Ala rich region and
the first half of Ig domain C1. Notably, similar splicing events
take place in the NH2-terminus of the mouse sMyBP-C tran-
script, giving rise to m-v4 and m-v002, which are homologous
to h-v4 and h-v002, respectively. Within the mouse transcrip-
tome, an additional splicing event has been described, leading
to the inclusion of all four exons, resulting in the generation
of an NH2-terminus similar to that of h-v1 and h-v2, however
the corresponding full-length mouse variant(s) has yet to be
determined.
Additional splicing events occur within the M-motif of the
human sMyBP-C transcript (Figure 2B). A simple splicing event
in h-v8 results in the exclusion of exon 10 that contains 54
nucleotides, resulting in the generation of an M-motif that
is 18 residues shorter than all other known human variants
(Figure 2B). To date, this splicing event has not been identified
in the mouse sMyBP-C transcript.
Within the region that encodes domain C7, exon 23 consist-
ing of 57 nucleotides is also subjected to alternative shuffling.
Variants h-v3, h-v5, h-v013, and h-v202 retain exon 23, and
thus contain 19 additional amino acids in the middle of FnIII
domain C7 (Figure 2C). The remaining variants lack exon 23 and
therefore encode a shorter domain C7. Notably, a similar splic-
ing even has been identified in the mouse sMyBP-C transcript;
however, the full length sequence of the relevant variant is still
unknown.
The extreme COOH-terminus of human sMyBP-C is another
“hot-spot” for complex alternative splicing. In particular, exons
31 and 32 are shuffled in and out resulting in four different com-
binations (Figure 2D, Table 2). When both exons are retained,
exon 31 encodes nineteen amino acids following Ig domain C10,
and exon 32 encodes another seven amino acids, a stop codon and
the immediate 3′UTR, while exon 33 contributes the remaining
3′UTR. When only exon 31 is included, following the 19 amino
acids that it encodes, there are 16 amino acids encoded by exon
33, which also contains a new stop codon and the entire 3′UTR.
Conversely, when only exon 32 is retained, it encodes three amino
acids following Ig domain C10, a stop codon, and the immedi-
ate 3′UTR, while exon 33 provides the remaining 3′UTR. Lastly,
when both exons 31 and 32 are spliced out, exon 33 encodes 33
amino acids following Ig domain C10, an alternate stop codon
and the entire 3′UTR.
The majority of the human sMyBP-C variants, including h-v1,
h-v6, h-v7, h-v8, h-v9, h-v002, and h-v202, retain both exons 31
and 32. On the other hand, h-v5 is the only known sMyBP-C vari-
ant that contains exon 31 but lacks exon 32. Moreover, sMyBP-C
variants h-v2, h-v3, h-v4, h-v012, and h-v013 lack exon 31, but
contain exon 32. Lastly, h-v10 is the only sMyBP-C variant that
lacks both exons 31 and 32. Splicing at the COOH-terminus of the
mouse sMyBP-C transcript also occurs, however, it has not been
as extensively described. Specifically, the COOH-termini of two
mouse slow variants, m-v002 and m-v4, match those of h-v002
and h-v4, respectively.
DISTINCT COMBINATIONS OF sMyBP-C VARIANTS ARE EXPRESSED IN
SINGLE MYOFIBERS ORIGINATING FROMMOUSE SOLEUS AND FDB
SKELETAL MUSCLES
We have previously shown that sMyBP-C variants are abun-
dantly expressed in both slow and fast twitch skeletal muscles,
and that distinct combinations of sMyBP-C variants are expressed
in different skeletal muscles (Ackermann and Kontrogianni-
Konstantopoulos, 2010, 2011). An outstanding question, how-
ever, is whether single fibers of the same skeletal muscle express
one or more sMyBP-C variant(s). To address this question, we
examined the expression profile of sMyBP-C variants in 48 and
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FIGURE 2 | Alternative splicing scheme of human MYBPC1. MYBPC1 undergoes extensive alternative splicing within the Pro/Ala rich region (A; exons 2–5),
M-motif (B; exon 10), domain C7 (C; exon 23), and at the extreme COOH-terminus (D; exons 31–33). Exon coloring corresponds to Figure 1.
Table 2 | Alternative splicing at the extreme COOH-terminus of sMyBP-C.
Variants Exon 31 Exon 32 Exon 33
h-v1, h-v6, h-v7, h-v8, h-v9, h-v002, h-v202, and m-v002 *CDS *CDS/Stop Codon/3′ UTR 3′ UTR
h-v5 *CDS – *CDS/Stop Codon/3′ UTR
h-v2, h-v3, h-v4, h-v012, h-v013, and m-v4 – *CDS/Stop Codon/3′ UTR 3′ UTR
h-v10 – – *CDS/Stop Codon/3′ UTR
*Coding sequence.
41 single fibers obtained from mouse slow twitch soleus and
fast twitch FDB muscles, respectively. Using western blot anal-
ysis and an antibody that recognizes epitopes in Ig domain C5
shared by all known sMyBP-C variants, we found that individual
soleus (Figure 3A) and FDB (Figure 3C) fibers contain distinct
combinations of sMyBP-C variants. In addition, we quantified
their relative abundance (Figures 3B,D), and determined the
percentage (%) of fibers expressing one, two, or three immunore-
active bands (Figure 3E). Given that the predicted molecular
weights of the different sMyBP-C variants are similar (Table 1),
along with the absence of variant-specific antibodies, we were
unable to determine the exact composition of sMyBP-C variants
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FIGURE 3 | Analysis of the expression profile of sMyBP-C variants in
slow twitch soleus and fast twitch FDB skeletal myofibers.
Endogenous myosin and sMyBP-C proteins were analyzed in single
fibers of adult mouse soleus (A) and FDB (C) muscles. The top part of
the gels was stained with SYPRO ruby total protein dye to observe the
different myosin isoforms (upper panels), while the bottom part of the
gels (lower panels) was processed for immunoblotting using antibodies
that recognize epitopes in Ig domain C5, which is present in all known
slow variants. Total protein content within each lane was evaluated by
Ponceau red staining, and found to be similar. We observed thirteen
and five possible expression patterns of sMyBP-C variants in the 48
soleus and 41 FDB fibers examined, respectively. Representative lanes
from multiple gels and corresponding blots depicting the expression
patterns of myosin and sMyBP-C are shown, and separated by a dotted
line; the frequency of each sMyBP-C pattern is noted under the
corresponding lane. (B–D) Slow variants were grouped according to
their predicted molecular weights, and then matched to the appropriate
immunoreactive band. The percent (%) expression of each group of
slow variants was quantified. (E) The number of variants per fiber was
calculated and reported as percent (%) occurrence.
in each fiber examined. We therefore calculated the approxi-
mate molecular weight of each immunoreactive band according
to its electrophoretic mobility, and correlated each band with
the respective group of sMyBP-C variants that it may encom-
pass; for instance, soleus fiber 1 contains an immunoreactive
band of ∼131 kDa, and thus may express v1 (∼131.5 kDa), v5
(∼131.5 kDa), or v202 (∼131 kDa), while FDB fiber 2 contains
an immunoreactive band of ∼129 kDa, and thus may contain v2
(∼129 kDa), v6 (∼129 kDa), or v013 (∼129.5 kDa). For ease of
presentation, we classified the sMyBP-C variants in six groups
according to their predicted molecular weights, with group 1
noted in red and including v1, v5, and v202 (131-131.5 kDa),
group 2 noted in orange and including v2, v6, and v013 (129–
129.5 kDa), group 3 noted in yellow and including v3, v7, and
v10 (128 kDa), group 4 noted in green and including v8 and v002
(127–127.5 kDa), group 5 noted in blue and including v4 and v9
(126–126.5 kDa), and group 6 noted in purple and including v012
(115.5 kDa).
Among the 48 soleus fibers that we assayed, we identi-
fied 13 different expression patterns of the sMyBP-C variants
(Figure 3A). Approximately 74% of soleus fibers expressed vari-
ants from two different groups, while ∼6% of fibers contained
variants from three groups, and the remaining ∼20% of fibers
expressed variants from one group (Figure 3E, white bars). Of the
fibers that contained variants from a single group, group 2 vari-
ants (v2, v6, and v013) were most abundantly expressed, being
present in ∼10% of the total fibers examined (Figure 3A, lane
3). Group 1 (v1, v5, and v202), 3 (v3, v7, and v10) and 4 (v8
and v002) variants were also expressed singly in ∼4, 4, and 2%
of the total fibers analyzed, respectively (Figure 3A, lanes 2,4,5).
Although group 5 variants (v4 and v9) were not observed singly,
they were occasionally co-expressed with variants from group 1
(v1, v5, v202), 4 (v8 and v002), or 6 (v012) in ∼2, 2, and 6%
of the total fibers assayed, respectively (Figure 3A, lanes 6, 11,
and 12). Similarly, group 6 variant (v012) was co-expressed with
group 1 (v1, v5, and v202), 2 (v2, v6, and v013), 3 (v3, v7, and
v10), 4 (v8 and v002), and 5 (v4 and v9) variants in ∼40, 12,
6, 4, and 6% of the total fibers examined (Figure 3A, lanes 7–11
and 13,14). Although co-expression of variants from three groups
was rare, it did occur among group 1 (v1, v5, and v202), 2 (v2,
v6, and v013), and 6 (v012) variants, and group 1 (v1, v5, and
v202), 3 (v3, v7, and v10), and 6 (v012) variants in ∼2 and 4%
of the total fibers tested, respectively (Figure 3A, lanes 13,14).
Thus, among the 13 different expression patterns of sMyBP-C
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that we identified in single soleus fibers, the most prominent one
was a combination of group 1 (v1, v5, and v202) and 6 (v012)
variants, which accounted for ∼40% of the total fibers examined
(Figure 3A, lane 7).
Contrary to soleus fibers, all 41 single FDB fibers assayed
exhibited the presence of sMyBP-C variants from only one group
(Figures 3C,E, black bars), resulting in five different expression
patterns. The majority (∼71%) of single FDB fibers expressed
group 1 (v1, v5, and v202) or group 2 (v2, v6, and v013) vari-
ants, which exhibited a ∼39 and 32% expression rate, respectively
(Figure 3C, lanes 2,3). Group 3 (v3, v7, and v10) and 4 (v8 and
v002) variants were also expressed singly with an ∼17 and 7%
occurrence rate, respectively (Figure 3C, lanes 4,5). Unique to
FDB fibers, group 5 variants (v4 and v9) were also expressed solely
in ∼5% of the total fibers examined (Figure 3C, lane 6), while
group 6 variants (v012) were not expressed either alone or in
combination with other sMyBP-C group variants. Thus, among
the five possible expression patterns of sMyBP-C that we observed
in single FDB fibers, group 1 variants were the most common,
which accounted for ∼39% of the total fibers tested (Figure 3A,
lane 2).
Using SYPRO ruby total protein stain, we further correlated
the expression profile of myosin isoforms with that of sMyBP-C
variants in single soleus and FDB fibers. Soleus muscle predom-
inantly expresses myosin isoforms I and IIa, while FDB mus-
cle mainly contains myosin isoforms IIa, IIx, and I (Calderon
et al., 2010; Drzymala-Celichowska et al., 2012). The majority
(∼82%) of soleus fibers possess both myosin I and IIa iso-
forms. These are co-expressed with eight out of the thirteen
possible combinations of sMyBP-C variants (Figure 3A lanes 3,4,
7–11; Table 3). The remaining 18% of soleus fibers contain solely
myosin I, which is co-expressed with the five additional com-
binations of sMyBP-C variants, (Figure 3A, lanes 2, 5,6, 12–14;
Table 3 | Correlation of sMyBP-C variant and myosin isoform
expression.
sMyBP-C Variant Expression Myosin isoform expression
Soleus muscle FDB muscle
v1, v5, and/or v202 I I and IIx
v2, v6, and/or v013 I I and IIa
v3, v7, and/or v10 I I and IIx
v8 and/or v002 I I, IIa, and IIx
v4 and/or v9 NA IIa
v1, v5, and/or v202 with v4 and/or v9 I NA
v1, v5, and/or v202 with v012 I and IIa NA
v2, v6, and/or v013 with v012 I and IIa NA
v3, v7, and/or v10 with v012 I and IIa NA
v8 and/or v002 with v012 I and IIa NA
v4 and/or v9 with v012 I and IIa NA
v8 and/or v002 with v4 and/or v9 I NA
v1, v5, and/or v202 with v2, v6, and I NA
v013 and/or with v012
v1, v5, and/or v202 with v3, v7, I NA
and/or v10 and with v012
Table 3). Conversely, FDB fibers expressing group 1 or group
3 variants (∼39 and 17%, respectively) possess myosins I and
IIx, fibers expressing group 2 variants (∼32%) contain myosins
I and IIa, fibers expressing group 4 variants (∼7%) encom-
pass myosins I, IIa, and IIx, while fibers expressing group 5 (v4
and v9) variants (∼5%) singly contain myosin IIa (Figure 3C,
Table 3).
THE EFFECT OF ALTERNATIVE SPLICING ON THE REGULATION,
LOCALIZATION, AND FUNCTION OF THE sMyBP-C VARIANTS
The sMyBP-C family of proteins is regulated via phosphoryla-
tion at its NH2-terminus within the Pro/Ala rich region and
the M-motif (Ackermann and Kontrogianni-Konstantopoulos,
2011). In particular, within the Pro/Ala rich region of the
mouse sequence, residues ser-59 and ser-62 are phosphory-
lated by PKA and residues ser-83 and thr-84 are phosphory-
lated by PKC. In addition, ser-204 within the M-motif is a
substrate of both PKA and PKC. Four of these five sites are
conserved in human sMyBP-C. Specifically, mouse ser-59, ser-
83, and ser-204 correspond to human ser-61, ser-85, and ser-
206, respectively, while mouse ser-62 aligns with human thr-64
(Figure 4).Mouse thr-84 is not conserved in the human sequence.
Although the phosphorylation potential of human sMyBP-C has
not been studied, it is likely that it also undergoes phospho-
rylation at these sites potentially mediated by PKA and PKC
(Figure 4).
Alternative splicing of the NH2-terminus adds another level of
complexity to the phosphorylation status of sMyBP-C.Within the
Pro/Ala rich region, all known human (h) and mouse (m) vari-
ants carry h-thr-64/m-ser-62 and h-ser-85/m-ser-83 (Figure 4A).
However, as these immediately follow the amino acid residues
encoded by exons 2–5, which are heavily spliced, their phos-
phorylation potential is likely dependent on the amino acid
sequences preceding them. This suggests that the extensive exon
shuffling occurring prior to h-thr-64/m-ser-62 and h-ser-85/m-
ser-83 may contribute to the regulation of each slow variant via
phosphorylation. Additional experiments are necessary to deter-
mine the extent to which alternative splicing affects the targeting
of h-thr-64/m-ser-62 and h-ser-85/m-ser-83 by PKA and PKC,
respectively.
Contrary to the constitutive expression of h-thr-64/m-ser-62
and h-ser-85/m-ser-83, h-ser-61/m-ser-59, and h-ser-206/m-ser-
204 are encoded by exons that are heavily spliced and thus
present only in select variants (Figures 4A,B). Human ser-61/m-
ser-59, encoded by exon 5 is only present in h-v1, h-v2 and
the corresponding mouse variants. The remaining human and
mouse variants lack exon 5 and do not express h-ser-61/m-ser-
59. Therefore, phosphorylation of h-ser-61/m-ser-59 via PKA
in the NH2-termini of variants 1 and 2 may contribute to
their differential regulation, and distinct modulatory effects on
the formation of actomyosin cross-bridges (discussed below).
Interestingly, h-v012 starts at exon 7; therefore it lacks all four
potential phosphorylation sites present within the Pro/Ala rich
region, suggesting that its regulation may differ from that of
the other variants. Moreover, h-ser-206/m-ser-204, present in
the M-motif, is encoded by exon 10 and is expressed in all
variants with the exception of h-v8. Thus, contrary to the
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FIGURE 4 | The NH2-terminus of sMyBP-C is subjected to complex
phosphorylation. sMyBP-C is phosphorylated within the Pro/Ala rich region
(A) and the M-motif (B). Alternating exons are noted in black and blue and
phosphorylation sites are shown in red. Amino acid residues
h-thr-64/m-ser-62, h-ser-85/m-ser-83, and m-thr-84 are present in constitutively
expressed portions of the Pro/Ala rich region. However, h-ser-61/m-ser-59 is
located within a segment that is alternatively spliced and therefore unique to
h-v1, h-v2, and the NH2-terminus of a partially characterized mouse variant
(m-partial-v1) matching that of h-v1 and h-v2. Moreover, human
h-ser-206/m-ser-204, located in the M-motif is present in all known sMyBP-C
variants, with the exception of h-v8 in which the respective exon (exon 10) is
skipped.
remaining sMyBP-C variants, the functional activities of v8 are
not regulated via PKA- or PKC-mediated phosphorylation of
h-ser-206/m-ser-204.
Early studies have documented that the sarcomeric localization
of MyBP-C isoforms is governed by their COOH-termini (Gilbert
et al., 1996, 1999; Ackermann et al., 2009). Therefore, small dif-
ferences in the amino acid composition of the COOH-terminus
of sMyBP-C due to alternative splicing may lead to alterations in
its subcellular targeting (Table 4). Consistent with this, sMyBP-
C variants v2, v3, v4, v012, and v013 that lack exon 31 localize
to the C-zone of the A-band (Gilbert et al., 1996, 1999), while
sMyBP-C variants v1, v6, v7, v8, v9, v002, and v202 that retain
exons 31 and 32 preferentially concentrate to the periphery of
the M-band (Ackermann et al., 2009). Moreover, given that the
COOH-termini of v5 and v10 are unique, lacking exon 32 and
exons 31 and 32, respectively, their subcellular distribution is still
unknown.
In light of the effect that alternative splicing has on the phos-
phorylation potential and subcellular localization of sMyBP-C
variants, it is safe to speculate that it also influences their func-
tional activities. Indeed, recent work from our group demon-
strated that the ability of sMyBP-C proteins to interact with
actin and myosin filaments, and modulate the formation of
actomyosin cross-bridges is variant-specific (Ackermann et al.,
2013). For instance, sMyBP-C v1 and v2, that retain exons 2–5,
exert the most potent regulatory effect on the formation of
actomyosin cross-bridges via their NH2-terminus by efficiently
interacting with both actin and myosin filaments. Moreover, v3,
v4, v5, v6, v8, and v202, which retain exons 2–3 also exhibit a
strong regulatory effect on the formation of actomyosin cross-
bridges by completing with actin filaments for binding to myosin
heads. Conversely, v002, which lacks exons 3–5, exerts a moder-
ate regulatory effect by interacting only with HMM. Given that
Table 4 | Sarcomeric localization of sMyBP-C variants.
Variant A-Band M-Band Unknown
h-v1 X
h-v2 X
h-v3 X
h-v4 X
h-v5 X
h-v6 X
h-v7 X
h-v8 X
h-v9 X
h-v10 X
h-v002 X
h-v012 X
h-v013 X
h-v202 X
m-v4 X
m-v002 X
the NH2-termini of v013, lacking only exon 5, v7, containing
only exon 3, v10, possessing only exon 4, and v9, lacking all
exons 2–5, are unique, further studies are necessary to deter-
mine their role in the modulation of actomyosin cross-bridges
formation.
Our studies have also shown that alternative splicing at the
COOH-terminus of sMyBP-C regulates the capacity of sMyBP-C
variants to interact with myosin thick and actin thin filaments in
a variant-specific manner (Ackermann et al., 2013). Accordingly,
sMyBP-C variants v2, v3, v4, v012, and v013 that lack exon 31
interact weakly with the light meromyosin (LMM) portion of
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myosin and actin thin filaments, while sMyBP-C variants v1, v6,
v7, v8, v9, v002, and v202 that retain exons 31 and 32 preferen-
tially interact with LMM. As the COOH-termini of v5 and v10 are
unique, lacking exon 32 and exons 31 and 32, respectively, their
ability to interact with thick and/or thin filaments is a point of
future studies.
CONCLUDING REMARKS
Herein we discuss the uniqueness and complexity of the slow
isoform of MyBP-C that distinguish it from its lone relatives,
the fast and cardiac isoforms. In particular, we focus on the
extensive alternative splicing that the MYBPC1 transcriptome
undergoes, leading to the generation of multiple variants that can
be differentially phosphorylated. We also present novel evidence
indicating that individual soleus and FDB fibers can express more
than one slow variant in select combinations, which coincide
with the presence of distinct myosin isoforms. Taken together,
it becomes apparent that sMyBP-C is a highly complex family
of proteins that can be co-expressed in the same muscle and
fiber, and potentially sarcomere and thick filament. Dissecting
the precise roles that each slow variant plays is an ambitious
task that will require a combination of molecular, cellular and
biochemical approaches alongside with the generation of the
appropriate animal models. The realization of the presence of
multiple sMyBP-C variants, which are expressed in distinct com-
binations among individual myofibers, is the first step toward
the elucidation of their differential roles in myofibrillar assem-
bly and actomyosin contractility. Thus, future work is warranted
in order to decipher the exact role of each slow variant during
development and adulthood in normalcy and disease. Lastly, as
a word of caution, given the immense complexity of the slow
family of MyBP-C proteins, it is imperative that we tailor our
questions, hypotheses, and methodologies in ways that will allow
the systematic and comprehensive characterization of the unique
properties and regulation of the MyBP-C slow subfamily, with-
out necessarily comparing it to its older relative, the cardiac
MyBP-C.
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